

1

Title Page

2 **Full title:** COVID-19 Associated Stroke—A Single Centre Experience

3 **Authors:**

4 1. Dr Uma Sundar¹, MD.

5 2. Dr Niteen D Karnik¹, MD.

6 3. Dr Amita Mukhopadhyay², MD.

7 4. Dr Pramod Darole³, MD.

8 5. Dr Shaonak Kolte⁴, MBBS.

9 6. Dr Ashank Bansal⁵, MD.

10 7. Dr Yojana A Gokhale¹, MD.

11 8. Dr Dnaneshwar Asole⁶, DNB (Neurology).

12 9. Dr Anagha Joshi⁷, MD.

13 10. Dr Sangeeta Pednekar¹, MD.

14 11. Dr Swati Chavan¹, MD.

15 12. Dr Trupti Trivedi¹, MD.

16 13. Dr Namita Padwal³, MD.

17 14. Dr Lalana Kalekar³, MD.

18 15. Dr Charulata Londhe³, MD.

19 16. Dr Rupal Padhiyar³, MD.

20 17. Dr Dharmendra Pandey³, MD.

21 18. Dr Dharendra Yadav⁶, MD.

22 19. Dr Sonal U Honrao⁶, MD.

23 20. Dr Prerana Bhavsar⁶, MD.

24 21. Dr Priyanshu Shah⁶, MD.

25 22. Dr Satish Gosavi⁸, MD.

- 26 23. Dr Aniket Wadal⁶, MD.
- 27 24. Dr Awesh P Shingare⁶, DNB (Endocrinology).
- 28 25. Dr Mayuri Trivedi⁶, DM (Nephrology).
- 29 26. Dr Gauri Pathak Oak⁶, MD.

30

31 **Author Affiliations:**

- 32 1. Professor, Medicine. Lokmanya Tilak Municipal Medical College and General
33 Hospital (LTMMC&GH), Sion, Mumbai 400022, Maharashtra, India.
- 34 2. Associate Professor, Community Medicine. Dr Chandramma Dayananda Sagar
35 Institute of Medical Education and Research, Kanakapura 562112, Ramanagara
36 District, Karnataka, India.
- 37 3. Associate Professor, Medicine. LTMMC&GH, Mumbai, India.
- 38 4. Research assistant, Medicine. LTMMC&GH, Mumbai, India.
- 39 5. Assistant Professor, Radiology. LTMMC&GH, Mumbai, India.
- 40 6. Assistant Professor, Medicine. LTMMC&GH, Mumbai, India.
- 41 7. Professor, Radiology. LTMMC&GH, Mumbai, India.
- 42 8. Senior resident, Medicine. LTMMC&GH, Mumbai, India.

43

44 Corresponding Author: Dr Uma Sundar

45 Email: umasundar2@rediffmail.com

46

47 Total number of tables and figures: Tables 4; Figures 3.

48 Word Count: Abstract 297; Text 3609.

49

50

51 **Abstract**

52 **Background and Purpose:** Various neurological complications have been reported in
53 association with COVID-19. We report our experience of COVID-19 with stroke at a single
54 center over a period of eight months spanning 1 March to 31 October 2020.

55 **Methods:** We recruited all patients admitted to Internal Medicine with an acute stroke, who
56 also tested positive for COVID-19 on RTPCR. We included all stroke cases in our analysis
57 for prediction of in-hospital mortality, and separately analyzed arterial infarcts for
58 vascular territory of ischemic strokes.

59 **Results:** There were 62 stroke cases among 3923 COVID-19 admissions (incidence 1.6%).
60 Data was available for 58 patients {mean age 52.6 years; age range 17–91; F/M=20/38; 24%
61 (14/58) aged ≤ 40 ; 51% (30/58) hypertensive; 36% (21/58) diabetic; 41% (24/58) with O₂
62 saturation $< 95\%$ at admission; 32/58 (55.17 %) in-hospital mortality}. Among 58 strokes,
63 there were 44 arterial infarcts, seven bleeds, three arterial infarcts with associated cerebral
64 venous sinus thrombosis, two combined infarct and bleed, and two of indeterminate type.
65 Among the total 49 infarcts, Carotid territory was the commonest affected (36/49; 73.5%),
66 followed by vertebrobasilar (7/49; 14.3%) and both (6/49; 12.2%). Concordant arterial block
67 was seen in 61% (19 of 31 infarcts with angiography done). ‘Early stroke’ (within 48 hours
68 of respiratory symptoms) was seen in 82.7% (48/58) patients. Patients with poor saturation at
69 admission were older (58 vs 49 years) and had more comorbidities and higher mortality (79%
70 vs 38%). Mortality was similar in young strokes and older patients, although the latter
71 required more intense respiratory support. Logistic regression analysis showed that low GCS
72 and requirement for increasing intensity of respiratory support predicted in-hospital mortality.
73 **Conclusions:** We had a 1.6% incidence of COVID-19 related stroke of which the majority
74 were carotid territory infarcts. In-hospital mortality was 55.17%, predicted by low GCS at
75 admission.

76 **Introduction:**

77 Various neurological complications, ranging from hypogeusia, headache and anosmia, to
78 Stroke, movement disorders, ataxia and myelitis, have been reported in association with
79 COVID-19.(1,2) Acute stroke has been documented as a life threatening complication of
80 COVID-19 in various reports since April 2020, the incidence reported ranging from 0.6% to
81 6%.(1–5) A pooled frequency of seven studies using the fixed effect model, estimated the
82 incidence of acute stroke in COVID-19 to be 1.1%.(6) The proposed mechanisms include a
83 virus induced prothrombotic state, endothelial injury, vasculitis, cardiomyopathy,
84 microvascular thrombosis and cytokine storm.(7–9) We report our experience of COVID-19
85 with stroke over a period of eight months spanning March to October 2020.

86 **Aims:** We aimed to document the incidence of acute strokes among COVID-19 presentations
87 at our hospital, to delineate the different types of strokes, and their possible mechanism. We
88 also aimed to evaluate severity of respiratory involvement, severity of the stroke, and
89 laboratory evidence of ongoing inflammation in these patients. Further, we aimed to
90 determine in-hospital outcome in terms of mortality, and to evaluate the independent clinical
91 and imaging predictors of mortality in stroke associated with COVID-19.

92 **Methods:**

93 Our study center is a 1400 bedded, tertiary care, municipal public hospital in Mumbai, India.
94 We performed a prospective and retrospective observational study with serial recruitment of
95 all patients who presented to the department of Internal Medicine with an acute stroke
96 between 1 March and 31 October 2020, who also had a reverse transcriptase-polymerase
97 chain reaction (RT-PCR) positive report for COVID-19. Patients were diagnosed with
98 COVID-19 using the RT-PCR tests conducted on samples collected either from a
99 nasopharyngeal or oropharyngeal swab. We included all patients with ischemic or
100 hemorrhagic strokes, and a combination of the two types (mixed group). We also included

101 three patients with associated additional cerebral venous sinus thrombosis (CVST) in this
102 study, who presented with a focal deficit and had a cerebral arterial infarct on imaging. We
103 included patients if the presentation was with the stroke and COVID-19 was detected later
104 during admission, as well as if the stroke developed during admission for COVID-19 related
105 respiratory symptoms. We did not include patients with a CVST without an arterial infarct or
106 bleed associated, in this study, as we are maintaining a separate registry of COVID-19
107 associated CVST at our center.

108 We noted the clinical, imaging and laboratory parameters in all patients, their respiratory
109 status at admission, and the modes of supplementary oxygen that they required to maintain an
110 oxygen saturation above 94% during hospital stay. The latter included, in order of increasing
111 intensity, nasal cannula, venturi mask, non-rebreathing bag and mask (NRBM), high flow
112 nasal cannula (HFNC), non-invasive ventilation (NIV), and intubation with mechanical
113 ventilation. Two independent radiologists reviewed and opined on the images with reference
114 to area of brain affected, vascular territory, and presence of large vessel occlusion (LVO) on
115 CT angiography. LVO was stated to be present if Internal Carotid artery (ICA), Vertebral,
116 Basilar, M1 or M2 segments of Middle Cerebral artery (MCA), Posterior Cerebral artery
117 (PCA) or Anterior Cerebral artery (ACA), were occluded.

118 We documented the presence of existing comorbidities after checking previous medical
119 records and ongoing medications prior to present admission. We classified patients who
120 developed stroke symptoms either prior to or simultaneous with, or within 48 hours of
121 respiratory symptom onset, as 'early stroke.'

122 We used Microsoft Excel (2010) to tabulate and clean the raw data, and to generate pivot
123 tables and graphs. We imported the excel datasheet into SPSS version 20.0 (Armonk, NY:
124 IBM Corp.) and performed univariate and multivariate analyses. We reported Mean \pm
125 Standard Deviation (SD) of key continuous variables. We divided the study set into

126 subgroups according to relevant characteristics and used the unpaired samples T-test and
127 Fisher's exact test to study differences in continuous and categorical variables, respectively.
128 We reported T tests with unequal variances assumed. We calculated 95% confidence
129 intervals for mean differences and odds ratios. We considered a p value below 0.05 to be
130 statistically significant if the 95% confidence intervals for the concerned test statistic were
131 congruent. We performed a binary logistic regression analysis to determine predictors of in-
132 hospital mortality. We entered the following variables as independent predictors: sex, age,
133 Glasgow Coma Scale (GCS) score, type of stroke (infarct, bleed, mixed infarct and bleed,
134 infarct with associated CVST, and strokes in which the type could not be determined,
135 classified as indeterminate), type of onset of stroke (early/late), the number of comorbidities,
136 the number of days that the patient was symptomatic prior to admission, the patient's oxygen
137 saturation level on room air at the time of admission, and respiratory distress level (coded on
138 an ascending scale reflecting the intensity of mode of supplementary oxygen delivery, where
139 0 represented no support required, and 6 represented invasive ventilation).

140 We included all the stroke cases in our analysis for prediction of in-hospital mortality, and
141 separately analyzed arterial infarcts (pure infarcts, and the infarct component from the mixed
142 and CVST groups) for vascular territory of ischemic strokes.

143 **Ethical considerations:** The Human Research Institutional Ethics Committee of Lokmanya
144 Tilak Municipal Medical College and General Hospital Mumbai, Maharashtra, India,
145 reviewed the study and granted it scientific and ethical approval.

146 **Data availability statement:** The data used in our analysis will be made available to
147 researchers upon reasonable request to the corresponding author.

148 **Results:**

149 During the period 1 March to 31 October 2020, there were 3923 COVID-19 admissions to the
150 medicine department at our center. Since ours is a tertiary care hospital, only patients
151 requiring oxygen support, or with any organ dysfunction, were admitted.

152 We had 62 stroke admissions during this period, giving an incidence of 1.6%. We were able
153 to collect detailed data for 58 out of these 62 patients (two patients had moved away to their
154 village and were untraceable after discharge, and two did not revert to our communication).

155 Table 1 shows the summarized clinical and laboratory findings for the cases. The mean age
156 was 52.6 years (range 17–91), with 20 out of 58 patients being women. The age and sex
157 distribution of the cases is shown in Figure 1. We had 14 patients (21% of 58) aged 40 years
158 or less, classified as ‘young strokes.’ Comorbidities taken into account were pre-existing
159 hypertension, diabetes mellitus, ischemic heart disease and chronic renal disease.

160 Hypertension was present in 51% (30/58) and Diabetes in 36% (21/58) patients. Among the
161 58 patients, 35% (20/58) had no comorbidities, 36% (21/58) had a single comorbidity and
162 29% (17/58) had two or more comorbidities.

163 Among 58 strokes, 44 were pure arterial infarcts, seven were arterial bleeds, two were mixed
164 (arterial infarct plus bleed), three had associated cerebral venous sinus thrombosis (CVST)
165 with cortical infarcts in the carotid territory (a total of 49 out of 58 patients thus had arterial
166 infarcts), and two were indeterminate (Figure 2A). These last were both bithalamic infarcts,
167 possibly due to blockage of artery of Percheron or vein of Galen. As CT angiography and
168 venography were not available for these two patients, they have been classified as of
169 indeterminate etiology.

170 Among the 49 patients with ischemic strokes either in isolation or in combination with CVST
171 or arterial bleed, 36 patients (36/49; 73.5%) had infarcts in the carotid territory, seven (7/49;
172 14.3%) in the vertebrobasilar territory, and six patients (6/49; 12.2%) had infarcts in both
173 territories. Among the carotid ischemic strokes (total 42), 39 scans were available for analysis

174 for type of carotid territory infarct. Among these, 16 were large hemispherical, 10 were
175 subcortical and 13 were pure cortical. A concordant arterial block was seen in 61% (19/31) of
176 the infarcts which had angiography done. The commonest vessels occluded were MCA main
177 stem (6/19), ICA extending into MCA (5/19), and ICA alone (3/19). (Figure 2B)

178 In this series, 82.7% (48/58) patients had an 'early stroke,' defined as development of stroke
179 symptoms either prior to or simultaneous with, or within 48 hours of respiratory symptom
180 onset. We noted 22/58 patients (37.9%) who presented to the emergency room with the
181 stroke, with no other associated respiratory or systemic symptoms. A comparative analysis of
182 patients with early versus late stroke, is shown in Supplementary Table S1.

183 Sixteen of 58 (28%) patients had already had over 72 hours of respiratory symptoms at home
184 before presentation. Six of these patients had stroke symptoms in addition, at home, but still
185 presented 72 hours or later after their first symptom. On analysis of these six patients, four
186 had a lacunar syndrome and four had GCS between 9 and 13 at admission.

187 In this series, 34/58 (58.6%) patients had normal oxygen saturation on room air (95% and
188 above) at presentation. There were 22/58 patients (37.9 %) with no respiratory symptoms
189 either, at presentation, with normal saturation on room air in casualty. Among the 34 patients
190 who had good oxygen saturation at admission, 22 continued to remain on room air, four went
191 on to nasal cannula at 4–5 liters/minute, one received venturi mask support at 8 liters/minute,
192 one through NRBM at 15 liters/minute, four received oxygen through NIV with average
193 positive end-expiratory pressure (PEEP) at 7 cm water, and two required intubation and
194 ventilation. Among the 24 patients who had poor oxygen saturation at admission, eight went
195 on to nasal cannula at 4–5 liters/minute, five received venturi mask support at 8 liters/minute,
196 one through NRBM at 15 liters/minute, one through HFNC at up to 60 liters/minute, eight
197 received oxygen through NIV at average PEEP 7 cm water, and one required intubation and
198 ventilation. Mortality in the former group was 38.2% and in the latter, 79.1%; a significant

199 difference. Comparison between these two groups (Table 2) showed that patients in the group
200 with poor saturation at admission were significantly older, and fewer of them were free of
201 comorbidities (20.8% vs 44.1% of patients with good saturation; although this was not
202 statistically significant).

203 Compared to younger patients, 40 years and under (24%; 14/58), older patients with stroke in
204 COVID-19 did not have notably higher mortality (Table 3). More of the older patients, as
205 expected, had associated comorbidities. Concordant arterial block (analyzed in a subset of 31
206 patients who had CT angiography reports available), was significantly commoner in the
207 younger group (100% in younger group vs 43% in older group). A larger proportion of the
208 younger patients, as compared to the older group, had normal oxygen saturation at admission.
209 In fact, 13/14 (92.8%) ‘young strokes’ did not progress beyond low flow systems (up to
210 venturi mask) in supplementary oxygen requirements during admission, whereas 17/44
211 (38.6%) older patients required respiratory support with NRBM, HFNC, NIV, or intubation
212 with mechanical ventilation. In contrast, the mortality was similar in both the groups (50% in
213 young strokes vs 56.8% in older strokes).

214 In our series, 47/58 patients were admitted after the beginning of July, when Remdesivir
215 injections became available to us. Patients with significant hypoxia, within 10 days of onset
216 of the first symptom of COVID-19, and with a normal creatinine clearance, qualified for
217 Remdesivir therapy. In this series, 19 of 47 patients received Remdesivir. Similarly,
218 Tocilizumab was available to us from early May (52 patients were admitted after this point),
219 and was administered to patients with a diagnosis of cytokine storm, as judged by persistent
220 hypoxia with diffuse lung involvement on CT chest, and raised inflammatory markers. In this
221 series, 7 of 52 patients received 400 mg of intravenous Tocilizumab. However, neither
222 Remdesivir nor Tocilizumab showed correlation with in-hospital survival in this series
223 (Supplementary Tables S2 and S3 respectively).

224 Figure 3 shows the timeline of stroke admissions in our series, in relation to overall COVID-
225 19 admissions from March to October 2020. Whereas there was a fall in COVID-19 cases
226 and flattening of the curve from August onwards, the maximum number of stroke admissions
227 (32/58) were in September and October 2020.

228 In-hospital mortality rate was 32/58 (55.17 %). Mortality among younger patients (≤ 40 yrs)
229 was 7/14 (50%). Binary logistic regression (Table 4) showed level of need for respiratory
230 support and GCS at admission to be independent predictors of mortality. Progression to more
231 intense modes of support correlated positively with mortality, and higher GCS at admission
232 correlated negatively. “Early Stroke” did not achieve significance in relation to mortality in
233 binary or multivariate analyses.

234 **Discussion:**

235 Our incidence of acute stroke during COVID-19 is 1.6%. However, this is probably an
236 underestimation. In the months of March and April 2020, we did not recognize that stroke
237 could be the first presentation of COVID-19. Hence, if the systemic or respiratory
238 involvement was mild or absent in COVID related strokes in the early months, the cases
239 could have been missed. Additionally, logistical problems of testing in the early months
240 contributed to the underestimation. We have not included cerebral venous sinus thrombosis in
241 this study, as mentioned, except in three cases where CVST was found on imaging in
242 association with a carotid territory infarct. The incidence of stroke in COVID-19 in other
243 reported studies ranged from 0.6% to 6%.(1–5,10–17) This wide range of reported incidence
244 is due to differing nature of data collection at different centers, with some studies reporting
245 only specific subtypes of strokes, and some others considering only severe cases of COVID-
246 19 for evaluation.

247 We classified the strokes as presenting early, or late, in relation to the first systemic symptom
248 of fever or respiratory complaints. This was to estimate the proportion of patients who had a

249 neurological presentation of COVID-19. In our series, 83% of patients with stroke had the
250 neurological symptoms within 48 hours of the first systemic/respiratory complaint. In fact, 22
251 patients (22/58; 37.9 %) had a pure neurological presentation, with no respiratory or systemic
252 symptoms at admission. This very early thromboembolic or hemorrhagic presentation argues
253 for a high thrombo-inflammatory pathology in these patients. In a meta-analysis of 28 articles
254 related to stroke and COVID-19, the average number of days to develop stroke among
255 patients after the onset of COVID-19 infection was 6.9 ± 4.5 days.(6) Some series, similar to
256 our data, have reported that patients may present with stroke with simultaneous asymptomatic
257 COVID-19 infection.(11,17) In concordance with stroke data in non-COVID-19 times, and
258 with data published on stroke in COVID-19, the vast majority of our CVAs were
259 infarcts.(13,15–17) The majority were in the Carotid territory. Over two thirds of the patients
260 who had an angiography done, showed concordant arterial blocks in the large vessels, MCA
261 main stem being the commonest vessel occluded. In the meta-analysis by Wei Lee et al.(6)
262 and in various studies,(3,11,17) occluded vessels involved were M1 vessels, M2 vessels,
263 internal carotid, multi-territorial, posterior cerebral, basilar, ACA, and the vertebral artery.
264 Mohamud et al have also raised the issue of Internal Carotid thrombosis in COVID-19
265 associated stroke being linked to cytokine storm.(18)

266 Although echocardiography is a mandatory investigation in acute ischemic stroke, we could
267 not perform this test in our patients due to logistical problems of transporting COVID-19
268 patients for tests, and not having a dedicated machine for echocardiography in the COVID-19
269 wards. We plan to do echocardiography in stable patients on follow up, after they are
270 COVID-19 negative. The elucidation of mechanism of ischemic stroke requires
271 determination of area of infarct, followed by, if required, angiography, echocardiography,
272 prolonged Holter monitoring and tests of coagulation if deemed necessary. During the
273 COVID-19 pandemic, it is not possible to do many of these tests in a resource challenged

274 setting, and the stroke may hence be labelled ‘cryptogenic,’ as investigations are limited.

275 Yaghi et al, comparing COVID positive and COVID negative strokes, reported a higher

276 incidence of both LVO and cryptogenic strokes among the former.(13)

277 Among our patients, 24% were 40 years of age or under. They had significantly fewer

278 comorbidities and higher oxygen saturation at admission, as compared to the older group.

279 Mortality was, however, similar in both groups, possibly contributed to by the significantly

280 higher proportion of proximal vessel occlusion in the younger group (100% in the young

281 group, vs 43% in the older group, in the patients who had a CT angiography done). This

282 could have led to rapidly worsening stroke and subsequent mortality, despite mild respiratory

283 illness. This is borne out by the fact that 13/14 of these young strokes had a mild respiratory

284 involvement, never requiring supplementary oxygen beyond venturi mask support. It is

285 possible that some of these young patients had tobacco or alcohol abuse as a risk factor for

286 stroke in the background. We do not have uniform data on tobacco and alcohol addiction

287 among our patients, hence these were not considered in the analysis. Various studies have

288 noted the association of COVID-19 with stroke in the young.(6,11,17,19) Belani et al have

289 reported a 7-fold increase in the rate of large vessel stroke in young people compared with the

290 previous year, in New York city, associated with a hypercoagulable state , due to COVID-

291 19.(20)

292 On comparing the patients who were admitted with a normal oxygen saturation with those

293 who had a low saturation at admission, we found significantly more patients with higher

294 mean age in the latter group, possibly leading to the higher mortality in this group. However,

295 subtype of stroke, level of inflammatory markers and presence of comorbidities were similar

296 in both groups. (Table 2)

297 Although a large proportion of our patients presented after both Remdesivir and Tocilizumab

298 became available to us for treatment, the addition of these did not appear to improve survival.

299 Remdesevir, which has been shown to reduce hospitalization time in COVID-19 with lower
300 respiratory involvement,(21) is unlikely to have much effect on the course of stroke in
301 COVID-19, which is multifactorial and complex in etiopathogenesis. Tocilizumab, which
302 binds specifically to both soluble and membrane-bound interleukin-6 receptors, is used in the
303 management of COVID-19 associated cytokine storm; however, whether it independently
304 results in survival benefit in severe COVID-19, is a matter for debate.(22,23) Although
305 cytokine storm has been proposed as an etiological factor in stroke in COVID-19, it is only
306 one of many proposed factors.

307 Since our hospital admits only the patients requiring a higher level of care, the curve of
308 overall COVID-19 admissions specifically reflects the most severe cases only (Figure 3).
309 Within this category, it is clear that the incidence of stroke increased as the number of severe
310 admissions fell, during August to October 2020. The explanation for this is unclear—it is
311 possible that the virus had a higher thromboinflammatory effect during this period, or
312 possibly some of the patients may have been reinfected after a previous mild illness and
313 recovery; patients and relatives could also have been more amenable to coming for admission
314 for stroke as the number of cases declined overall in the city.

315 In this series, 55% of patients expired in hospital. We found lower GCS score at admission
316 to be an independent predictor of in-hospital mortality in stroke with COVID-19, as expected,
317 signifying a worse stroke. Requirement for higher levels of respiratory support also predicted
318 mortality, signifying more severe respiratory and neurological illness overall. Early onset of
319 stroke, longer duration of symptoms at home before presenting to hospital, and oxygen
320 saturation at admission showed no correlation with in-hospital mortality. In three studies
321 comparing stroke in COVID-19 patients with stroke in non-COVID-19 patients, mortality
322 was higher in all three cohorts among patients with COVID-19 infection; Benussi et al.(16)
323 reporting 34.9% vs. 5.9%, Yaghi et al.(13) reporting 63.6% vs. 9.3%, and Escalard et al.(24)

324 reporting 60.0% vs. 11.0%, respectively. Taylor et al reported a mortality of 46% among their
325 patients, with a high percentage of proximal LVOs.(25)

326 We faced many management dilemmas during the treatment of these 58 patients. In the initial
327 months, patients would not be brought on time, or not brought at all to hospital, due to fear of
328 COVID-19 among relatives. Although six patients were brought in the golden period for
329 intravenous thrombolysis, and one developed ischemic stroke while in the ward, intravenous
330 thrombolysis was not possible in any of them due to various factors—severe respiratory
331 disease, or severe stroke, and in one case, absence of relatives to sign consent, due to
332 quarantine. We detected only a single patient with platelet count below 50000/ c mm during
333 admission, in our study. Hence, apprehensions about thrombocytopenia should probably not
334 hinder the decision to thrombolysse immediately, if the patient meets criteria for intravenous
335 thrombolysis.

336 We follow a policy of anticoagulation with Heparin during admission, in all patients with
337 moderate to severe COVID-19 requiring oxygen supplementation, who have raised d Dimer
338 over twice normal levels. Similarly, we discharge moderate to severe COVID-19 patients on
339 oral anticoagulants, to be taken for 4-6 weeks, to prevent thromboembolic episodes, in line
340 with current guidelines.(26,27) In the presence of a large infarct with attendant advanced age
341 or uncontrolled hypertension, there is a risk of a secondary bleed into the infarct while on
342 Heparin. We decided the dose and type of Heparin during hospital stay, and the oral
343 anticoagulant at discharge, on a case to case basis. We prescribed a single antiplatelet at
344 discharge in addition to the oral anticoagulant, in the majority of our patients. Treatment of
345 COVID positive ischemic stroke, in the available literature, has ranged from mechanical
346 thrombectomy in very stable patients, to standard oral antiplatelet therapy,(3,24,28,29)
347 reflecting the wide variability in severity of stroke as well as respiratory illness, in them.

348 In conclusion, we had an incidence of 1.6%, of COVID-19 related stroke in our center. Of
349 these 84% were infarcts, with the majority being in the Carotid territory. Young strokes
350 comprised 24% of the patients. Concordant arterial occlusion was seen in 61% of the patients
351 who had an angiography done, and was significantly more frequent in younger patients
352 compared to older patients, in our study group. In-hospital mortality was 55.17% and was
353 predicted by a low GCS at admission and higher levels of respiratory support required to
354 maintain saturation. Management dilemmas included the role of anticoagulation during
355 admission and at discharge, taking into account the importance of preventing further
356 thromboembolic complications vs the risk of secondary bleeding into large infarcts.

357 **Sources of Funding:** None

358 **Disclosures:** None

359

360 **References:**

- 361 1. Correia AO, Feitosa PWG, Moreira JL de S, Nogueira SÁR, Fonseca RB, Nobre MEP.
362 Neurological manifestations of COVID-19 and other coronaviruses: A systematic
363 review. *Neurol Psychiatry Brain Res.* 2020 Sep;37:27–32.
- 364 2. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological
365 associations of COVID-19. *Lancet Neurol.* 2020;19(9):767–83.
- 366 3. Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-Vessel
367 Stroke as a Presenting Feature of Covid-19 in the Young. *N Engl J Med.* 2020
368 14;382(20):e60.
- 369 4. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of
370 Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol.*
371 2020 01;77(6):683–90.

- 372 5. Khandelwal P, Mufti FA, Tiwari AT, Singla A, Dmytriw A, Piano M, et al. Incidence,
373 Characteristics and Outcomes of Large Vessel Stroke in COVID-19 Cohort: A
374 Multicentric International Study. [Internet]. Rochester, NY: Social Science Research
375 Network; 2020 Jun [cited 2020 Dec 1]. Report No.: ID 3617195. Available from:
376 <https://papers.ssrn.com/abstract=3617195>
- 377 6. Lee KW, Yusof Khan AHK, Ching SM, Chia PK, Loh WC, Abdul Rashid AM, et al.
378 Stroke and Novel Coronavirus Infection in Humans: A Systematic Review and Meta-
379 Analysis. *Front Neurol.* 2020;11:579070.
- 380 7. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue
381 distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step
382 in understanding SARS pathogenesis. *J Pathol.* 2004 Jun;203(2):631–7.
- 383 8. Moore HB, Barrett CD, Moore EE, McIntyre RC, Moore PK, Talmor DS, et al. Is there
384 a role for tissue plasminogen activator as a novel treatment for refractory COVID-19
385 associated acute respiratory distress syndrome? *J Trauma Acute Care Surg.*
386 2020;88(6):713–4.
- 387 9. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological
388 features of severe and moderate coronavirus disease 2019. *J Clin Invest.* 2020
389 01;130(5):2620–9.
- 390 10. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous
391 and arterial thromboembolic complications in COVID-19 patients admitted to an
392 academic hospital in Milan, Italy. *Thromb Res.* 2020;191:9–14.
- 393 11. Avula A, Nalleballe K, Narula N, Sapozhnikov S, Dandu V, Toom S, et al. COVID-19
394 presenting as stroke. *Brain Behav Immun.* 2020;87:115–9.

- 395 12. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D a. MPJ, Kant
396 KM, et al. Incidence of thrombotic complications in critically ill ICU patients with
397 COVID-19. *Thromb Res.* 2020;191:145–7.
- 398 13. Yaghi S, Ishida K, Torres J, Mac Grory B, Raz E, Humbert K, et al. SARS-CoV-2 and
399 Stroke in a New York Healthcare System. *Stroke.* 2020;51(7):2002–11.
- 400 14. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al.
401 High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter
402 prospective cohort study. *Intensive Care Med.* 2020;46(6):1089–98.
- 403 15. Xiong W, Mu J, Guo J, Lu L, Liu D, Luo J, et al. New onset neurologic events in people
404 with COVID-19 in 3 regions in China. *Neurology.* 2020 15;95(11):e1479–87.
- 405 16. Benussi A, Pilotto A, Premi E, Libri I, Giunta M, Agosti C, et al. Clinical characteristics
406 and outcomes of inpatients with neurologic disease and COVID-19 in Brescia,
407 Lombardy, Italy. *Neurology.* 2020 18;95(7):e910–20.
- 408 17. Fara MG, Stein LK, Skliut M, Morgello S, Fifi JT, Dhamoon MS. Macrothrombosis and
409 stroke in patients with mild Covid-19 infection. *J Thromb Haemost.* 2020
410 Aug;18(8):2031–3.
- 411 18. Mohamud AY, Griffith B, Rehman M, Miller D, Chebl A, Patel SC, et al. Intraluminal
412 Carotid Artery Thrombus in COVID-19: Another Danger of Cytokine Storm? *AJNR*
413 *Am J Neuroradiol.* 2020;41(9):1677–82.
- 414 19. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and
415 Antiphospholipid Antibodies in Patients with Covid-19. *N Engl J Med.* 2020 Apr
416 8;382(17):e38.
- 417 20. Belani P, Schefflein J, Kihira S, Rigney B, Delman BN, Mahmoudi K, et al. COVID-19
418 Is an Independent Risk Factor for Acute Ischemic Stroke. *AJNR Am J Neuroradiol.*
419 2020;41(8):1361–4.

- 420 21. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al.
421 Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med*. 2020
422 05;383(19):1813–26.
- 423 22. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al.
424 Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. *N Engl J Med*. 2020
425 21;
- 426 23. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al.
427 Tocilizumab in patients with severe COVID-19: a retrospective cohort study. *Lancet*
428 *Rheumatol*. 2020 Aug;2(8):e474–84.
- 429 24. Escalard S, Maïer B, Redjem H, Delvoe F, Hébert S, Smajda S, et al. Treatment of
430 Acute Ischemic Stroke due to Large Vessel Occlusion With COVID-19: Experience
431 From Paris. *Stroke*. 2020;51(8):2540–3.
- 432 25. Taylor BES, Khandelwal P, Rallo MS, Patel P, Smith L, Sun H, et al. Outcomes and
433 Spectrum of Major Neurovascular Events Among COVID-19 Patients: A 3-Center
434 Experience. *Neurosurgery Open* [Internet]. 2020 Sep [cited 2020 Dec 1];1(3). Available
435 from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454798/>
- 436 26. Flaczyk A, Rosovsky RP, Reed CT, Bankhead-Kendall BK, Bittner EA, Chang MG.
437 Comparison of published guidelines for management of coagulopathy and thrombosis in
438 critically ill patients with COVID 19: implications for clinical practice and future
439 investigations. *Crit Care*. 2020 16;24(1):559.
- 440 27. Chowdhury JF, Moores LK, Connors JM. Anticoagulation in Hospitalized Patients with
441 Covid-19. *N Engl J Med*. 2020 Oct 22;383(17):1675–8.
- 442 28. TunÇ A, ÜnlÜbaŞ Y, Alemdar M, AkyÜz E. Coexistence of COVID-19 and acute
443 ischemic stroke report of four cases. *J Clin Neurosci*. 2020 Jul;77:227–9.

444 29. Qureshi AI, Abd-Allah F, Al-Senani F, Aytac E, Borhani-Haghighi A, Ciccone A, et al.
445 Management of acute ischemic stroke in patients with COVID-19 infection: Insights
446 from an international panel. Am J Emerg Med. 2020;38(7):1548.e5-1548.e7.

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461 **Tables:**

462 Table 1 COVID-19 with Stroke: Overall Data

Parameter	Mean±SD	Range
Age	52.6±15.47	17–91
GCS score	9.31±4.08	3–15
SpO2 at admission	89.16±13.30	46–99
Platelet count/μL (n=53)	220718±106107	20100–607000

CRP mg/L (n=31)	61.88±58.23	2.8–229
D Dimer ng/mL (n=27)	2796.3±2389.6	335–10000
D Dimer nmol/L (n=27)	30.62±26.17	3.67–109.52
S. Creatinine mg/dL (n=54)	1.22±0.70	0.4–5.2
S. Creatinine μmol/L (n=54)	107.88±61.47	35.36–459.68
Gender ratio M/F (%)	38/20 (66:34)	
Pts with ≥1 comorbidity (%)	38/58 (65)	
Infarcts/Pure Bleeds (% of 58)	49/7 (84/12)	
Carotid/Vertebrobasilar/Both (%)	36/7/6 (73.4/14.3/12.3)	
Proximal arterial block (%)	19/31 (61)	
SpO2 < 95% at admission (%)	24/58 (41)	
Mortality (%)	32/58 (55.17)	

463 CRP: C Reactive Protein

464

465

466

467 Table 2 COVID-19 associated stroke patients with good saturation* at admission compared

468 to those with low saturation.

Parameter	Good saturation n=34	Poor saturation n=24	P value	Test statistic (95% CIs)
Pure Ischemia/Pure Bleed	24/5	20/2		
Mean Age	48.62	58.25	.016	-9.63 [†] (-17.39 – -1.87)

Mean GCS	9.41	9.17	.826	0.24 [†] (-1.99 – 2.48)
Mean D Dimer nmol/L [§]	28.13	33.74	.596	-5.60 [‡] (-27.22 – 16.01)
Mean CRP mg/L	49.15	77.35	.207	-28.20 [‡] (-73.29 – 16.88)
Large hemispherical infarcts	9/34	7/24	.999	0.87 [‡] (0.27 – 2.80)
Comorbidities \geq 1	19/34	19/24	.094	0.33 [‡] (0.10 – 1.10)
Mortality (%)	13 (38.2)	19 (79.2)	.003	0.16 [‡] (0.05 – 0.54)

469 *SpO₂>95 % on room air; † Test statistic: Mean difference; ‡ Test statistic: Odds ratio; § D

470 Dimer values available for 15 patients with good saturation and 12 with poor saturation; ||

471 CRP values available for 17 patients with good saturation and 14 with poor saturation; CRP:

472 C Reactive Protein

473

474

475

476

477

478

479

480

481 Table 3 Young strokes* in COVID-19: a comparison with older strokes

Parameter	Young (n=14)	Older (n=44)	P Value	Test statistic (95% CIs)
Pure Ischemia/Pure Bleed	10/1	34/6		
Mean Age	31.79	59.23	.000	-27.44 [†] (-32.41 – -22.48)
Mean GCS	9.93	9.11	.516	0.81 [†] (-1.74 – 3.37)

Mean D Dimer nmol/L [§]	49.03	26.44	.215	22.59 (-18.43 – 63.60)
Mean CRP mg/L	47.87	65.25	.560	-17.38 [†] (-84.38 – 49.61)
Mean SpO2 at admission	96.71	86.75	.000	9.96 [†] (5.47 – 14.45)
Large hemispherical infarcts	5/14	11/44	.500	1.67 [‡] (0.46 – 6.05)
Comorbidities ≥1	3/14	35/44	.000	0.07 [‡] (0.02 – 0.31)
Concordant arterial block [#]	10/10	9/21	.004	NA (denominator 0)
Respiratory support ≥NRBM	1/14	17/44	.044	0.12 [‡] (0.01 – 1.02)
Mortality (%)	7 (50.0)	25 (56.8)	.761	0.76 [‡] (0.23 – 2.54)

482 * Age ≤40; † Test statistic: Mean difference; ‡ Test statistic: Odds ratio; § D Dimer values
 483 available for 5 young strokes and 22 older patients; || CRP values available for 6 young
 484 strokes and 25 older patients; # 31 CT angiographies done; CRP: C Reactive Protein

485

486

487

488

489

490

491

492 Table 4 Predictors of In-hospital Mortality in COVID-19

	B	Exp(B)	95% C.I. for EXP(B)		Sig.
			Lower	Upper	
Sex (M)	0.03	1.03	0.15	7.02	.975
Age	-0.04	0.96	0.90	1.03	.259
Respiratory support	1.01	2.75	1.15	6.57	.022

intensity					
Duration of symptoms	-0.13	0.88	0.77	1.01	.060
GCS score	-0.37	0.69	0.54	0.89	.004
SpO2 at Admission	-0.06	0.94	0.86	1.04	.234
Stroke type (ref. bleed)					.722
Infarct	-1.17	0.31	0.02	4.36	.385
Infarct+Bleed	0.23	1.25	0.00	350.03	.937
Infarct+CVST	-4.07	0.02	0.00	10.74	.216
Indeterminate	19.07	1.91e08	0.00		.999
Early onset stroke	-1.00	0.37	0.02	5.79	.477
No. of comorbidities	0.23	1.26	0.44	3.63	.666
Constant	11.75	126808.17			.044

493 CVST: Cerebral Venous Sinus Thrombosis

494

495


496

497

498

499 **Figures:**

500 Figure 1 Age-Sex Distribution of COVID Stroke Cases



501

502

503

504

505

506

507

508

509

510

511

512

513

514


515

516

517

518 Figure 2A: Types of Stroke in COVID Stroke Patients and 2B: Large Vessel Occlusion

519 Types among Arterial Infarcts



520

521 CVST: Cerebral Venous Sinus Thrombosis; MCA M1: M1 segment of Middle Cerebral
522 artery; ICA: Internal Carotid artery; ACA: Anterior Cerebral artery; MCA M2: M2 segment
523 of Middle Cerebral artery. CT Angiographies done in 31 of whom 19 had concordant arterial
524 blocks.

525


526

527

528

529 Figure 3: Time Trend of COVID Stroke Cases vs Total COVID-19 Admissions to

530 Internal Medicine



531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

COVID-19 Associated Stroke—A Single Centre Experience

551

552 Uma Sundar, Niteen D Karnik, Amita Mukhopadhyay, Pramod Darole, Shaonak
553 Kolte, Ashank Bansal, Yojana A Gokhale, Dnaneshwar Asole, Anagha Joshi, Sangeeta
554 Pednekar, Swati Chavan, Trupti Trivedi, Namita Padwal, Lalana Kalekar, Charulata
555 Londhe, Rupal Padhiyar, Dharmendra Pandey, Dhirendra Yadav, Sonal U Honrao, Prerana
556 Bhavsar, Priyanshu Shah, Satish Gosavi, Aniket Wadal, Awesh P Shingare, Mayuri Trivedi,
557 Gauri Pathak Oak.

558

559 **SUPPLEMENTARY MATERIAL**

560 *Table of Contents*

561	Supplementary Tables:	28
562	Table S1 COVID-19 associated stroke patients with early stroke vs. those with late stroke	28
563	Table S2 Analysis of patients admitted after Remdesivir became available	29
564	Table S3 Analysis of patients admitted after Tocilizumab became available.....	30

565

566

567

568

569

570

571

Supplementary Tables:

572

Table S1 COVID-19 associated stroke patients with early stroke vs. those with late stroke

573

Parameter	Early stroke* n=48	Late stroke n=10	P value	Test statistic (95% CIs)
Pure Ischemia/Pure Bleed	36/6	8/1		
Mean Age	52.79	51.70	.832	1.09 [†] (-9.73 – 11.91)
Mean GCS	9.44	8.70	.638	0.74 [†] (-2.59 – 4.06)
Mean D Dimer nmol/L [§]	30.71	29.98	.962	0.73 [†] (-45.18 – 46.63)
Mean CRP mg/L	67.62	38.00	.051	29.62 [†] (-0.07 – 59.31)
Large hemispherical infarcts	14/48	2/10	.710	1.65 [‡] (0.31 – 8.75)
Comorbidities \geq 1	31/48	7/10	.999	0.78 [‡] (0.18 – 3.42)
Mortality (%)	27/48 (56.2)	5/10 (50.0)	.740	1.29 [‡] (0.33 – 5.03)

574

*Stroke developed prior to, simultaneous with or within 48 hours after respiratory symptoms;

575

[†] Test statistic: Mean difference; [‡] Test statistic: Odds ratio; [§] D Dimer values available for

576

24 early strokes and 3 late strokes; ^{||} CRP values available for 25 early strokes and 6 late

577

strokes.

578

579

580

581

582

583

584

585

586

587

588

589

590

591 Table S2 Analysis of patients admitted after Remdesivir became available
592

Parameter	Received Rem*, n=19	Did not receive Rem, n=28	P value	Test statistic (95% CIs)
Pure Ischemia/Pure Bleed	15/2	19/4		
Mean Age	54.95	51.79	.510	3.16 [†] (-6.45 – 12.77)
Mean SpO2 at admission	87.16	90.54	.427	-3.38 [†] (-11.88 – 5.13)
Mean GCS	9.42	9.32	.935	0.10 [†] (-2.36 – 2.56)
Mean D Dimer nmol/L§	29.57	32.16	.806	-2.59 [†] (-24.22 – 19.04)
Mean CRP mg/L	58.18	66.38	.705	-8.21 [†] (-52.23 – 35.81)
Mean Creatinine μmol/L#	102.36	120.36	.317	-18.00 [†] (-54.01 – 18.00)
Large hemispherical infarcts	4/19	8/28	.737	0.67 [‡] (0.17 – 2.63)
Comorbidities ≥1	10/19	19/28	.365	0.53 [‡] (0.16 – 1.75)
Mortality (%)	10/19 (52.6%)	14/28 (50.0%)	.999	1.11 [‡] (0.35 – 3.57)

593 *Remdesivir available for use post July 1, n = 47; † Test statistic: Mean difference; ‡ Test
594 statistic: Odds ratio; § D Dimer values available for 16 patients who received Remdesivir and
595 11 who did not; || CRP values available for 17 patients who received Remdesivir and 14 who
596 did not; # Creatinine values available for 19 patients who received Remdesivir and 26 who
597 did not.

598
599
600
601
602
603
604
605
606
607
608
609
610

611 Table S3 Analysis of patients admitted after Tocilizumab became available

612

613

	Received Toci*, n=7	Did not receive Toci, n=45	P value	Test statistic (95% CIs)
Pure Ischemia/Pure Bleed	6/0	32/7		
Mean Age	67.00	50.13	.005	16.87 [†] (6.40 – 27.33)
Mean SpO2 at admission	82.43	90.76	.117	-8.33 [‡] (-19.21 – 2.56)
Mean GCS	9.29	9.09	.909	0.20 [‡] (-3.62 – 4.02)
Mean D Dimer nmol/L§	27.15	31.84	.605	-4.69 [‡] (-23.28 – 13.91)
Mean CRP mg/L	93.17	54.38	.260	38.79 [‡] (-36.99 – 114.58)
Mean Creatinine μmol/L#	1.36	1.22	.520	12.04 [‡] (-27.41 – 51.49)
Large hemispherical infarcts	2/7	12/45	.999	1.10 [‡] (0.19 – 6.44)
Comorbidities ≥1	6/7	26/45	.228	4.38 [‡] (0.49 – 39.50)
Resp. support ≥NRBM	5/7	13/45	.041	6.15 [‡] (1.06 – 35.84)
Mortality (%)	3/7 (42.9%)	24/45 (53.3%)	.698	0.66 [‡] (0.13 – 3.27)

614 *Tocilizumab available for use post May 13, n = 52; † Test statistic: Mean difference; ‡ Test
 615 statistic: Odds ratio; § D Dimer values available for 7 patients who received Tocilizumab and
 616 20 who did not; || CRP values available for 6 patients who received Tocilizumab and 25 who
 617 did not; # Creatinine values available for 7 patients who received Tocilizumab and 43 who
 618 did not.

619